There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zynerba Pharmaceuticals (ZYNE), RedHill Biopharma (RDHL) and Principia Biopharma Inc (PRNB) with bullish sentiments.
Zynerba Pharmaceuticals (ZYNE)
Needham analyst Serge Belanger initiated coverage with a Buy rating on Zynerba Pharmaceuticals today and set a price target of $18.00. The company’s shares closed last Monday at $8.05.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -3.2% and a 39.2% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Collegium Pharmaceutical, and Flexion Therapeutics.
Currently, the analyst consensus on Zynerba Pharmaceuticals is a Strong Buy with an average price target of $19.20.
See today’s analyst top recommended stocks >>
RedHill Biopharma (RDHL)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on RedHill Biopharma today and set a price target of $16.00. The company’s shares closed last Monday at $6.35.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -10.5% and a 31.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, Corcept Therapeutics Inc, and IntelGenx Technologies.
RedHill Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
Principia Biopharma Inc (PRNB)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Principia Biopharma Inc today and set a price target of $57.00. The company’s shares closed last Monday at $30.25.
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.6% and a 27.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Principia Biopharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $54.00, implying a 73.1% upside from current levels. In a report issued on October 10, Stifel Nicolaus also maintained a Buy rating on the stock with a $51.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
